What the Clinical Data Actually Shows The most definitive comparison comes from the SURMOUNT-5 trial, a direct head-to-head study published in the New England Journal of Medicine comparing tirzepatide 10 mg and 15 mg against semaglutide 2.4 mg in adults with obesity but without diabetes
In early trials, a transient increase in heart rate was observed around the 24-week mark before gradually declining
GI symptoms: Record nausea, bloating, constipation, or diarrhea with severity (mild, moderate, severe) and duration
Other types of birth control may still be effective with semaglutide as they do not involve the digestive system
The regain is not permanentrestarting GLP-1 therapy prompts renewed loss
A study over six months with 822 participants having type 2 diabetes revealed similar weight loss when either Rybelsus or Jardiance was used in conjunction with another diabetes medication